People taking part in the study will be randomly assigned to receive either one injection of the experimental treatment or regular injections of the approved medication. Before starting the main part of the study, participants will receive one injection of the approved medication to make sure their condition responds to this type of treatment. During the study, doctors will measure vision using an eye chart and will take images of the eye to see how the condition is changing. The main measurement will be the change in vision after one year of treatment. Doctors will also track how many additional injections are needed and whether the experimental treatment can reduce the need for repeated injections compared to the standard treatment.

The study will last several years and will continue to follow participants to see how long the effects of the treatments last. Throughout the study, participants will have regular visits where their vision will be tested and their eyes will be examined. The study aims to determine whether the single injection of gene therapy can provide lasting benefits and reduce the treatment burden for people with this eye condition.

Participants in the study will receive two initial high doses of the medication. Following these starting doses, the study will observe the effects on the eye over several weeks. This includes monitoring changes in visual acuity, which is the clarity or sharpness of vision, and checking for any fluid in the macula, the central part of the retina responsible for detailed vision. Specialized imaging such as optical coherence tomography, a non-invasive way to take cross-section pictures of the retina, may be used to look at the thickness of the retinal layers and the presence of fluid.

The purpose of this study is to find out how many injections people need after receiving the gene therapy compared to those who continue getting regular injections of ranibizumab, and to see how well the gene therapy works in preserving vision over time in a setting that is similar to everyday medical practice. The study will also look at the safety of the gene therapy and measure any side effects that may occur in the treated eye or the other eye. Additionally, the study will check for changes in areas of damage in the central part of the retina.

People taking part in the study will be randomly assigned to receive either the gene therapy or ranibizumab. Those who receive the gene therapy will have it injected under the retina during a surgical procedure, while those in the comparison group will receive ranibizumab injections into the eye as needed based on how their condition responds. During the first year, people will be monitored closely and receive additional injections if needed according to specific guidelines. After the first year, the treatment schedule will follow a more flexible approach that reflects how treatment is typically managed in regular clinics. The study will last for several years to see how well vision is maintained over the long term.

The purpose of this research is to evaluate how well the Port Delivery System works when the medicine is refilled every 36 weeks. The medication being studied, ranibizumab, is already approved for treating wet AMD when given as regular eye injections. In this study, participants will receive the implanted delivery system and will have it refilled with medication according to a set schedule over approximately 72 weeks.

During the study, patients will have regular eye examinations and vision tests to monitor their condition. The Port Delivery System will be surgically implanted into the eye at the beginning of the study, and then the medicine will be refilled through this system. The study will compare this new delivery method to traditional eye injections and will monitor both the effectiveness of the treatment and any side effects that may occur.

The purpose of this research is to monitor participants who previously received ABBV-RGX-314 in earlier clinical trials to evaluate its long-term safety and effectiveness. The study includes follow-up assessments of vision using best-corrected visual acuity (BCVA) testing and measurements of central retinal thickness (CRT) using specialized imaging. The study also tracks how many additional anti-VEGF (vascular endothelial growth factor) injections participants might need over time. Anti-VEGF medications help control the growth of abnormal blood vessels in the eye.

Additionally, this study includes a “Fellow Eye Treatment Substudy” which will evaluate treatment in the other eye of participants who have nAMD in both eyes. Participants will be monitored for any side effects and changes in their vision over a period of several years.

The purpose of this study is to determine how well faricimab works and how safe it is when given to patients over extended periods, with treatments spaced up to 24 weeks apart. The medication is provided as a solution for injection with a strength of 120 mg/mL. During the study, participants will receive eye injections according to different schedules, and their vision will be monitored regularly.

The study will track changes in participants’ vision and examine the thickness of specific layers in the retina over time. The treatment period lasts for approximately 96 weeks, during which patients will receive regular eye examinations and vision tests. The study will monitor both the benefits of the treatment and any side effects that may occur in the eye or elsewhere in the body.

The study involves a single group of participants who will receive a one-time dose of the treatment. Healthcare professionals will follow specific instructions to prepare and give the injection. The main goal is to see how effectively these instructions can be followed. Participants will be monitored for any side effects or changes in their vision over a short period, typically up to a week after the injection.

Throughout the study, the focus will be on the ease of use of the pre-filled syringe and the safety of the treatment. The study will also look at any improvements in vision that may occur after the injection. This research is important for understanding how this new method of delivering ranibizumab can be used in treating these eye conditions effectively and safely.

The purpose of the study is to evaluate how well EYP-1901 works in comparison to aflibercept in improving vision. Participants in the study will receive either the EYP-1901 implant or aflibercept injections. The study will last for up to 96 weeks, during which time the effects of the treatments on vision and the structure of the retina, the light-sensitive layer at the back of the eye, will be monitored. The study will also look at how many additional injections of aflibercept might be needed over the course of the study.

Throughout the study, changes in vision and the thickness of the retina will be assessed. The primary goal is to determine if EYP-1901 can provide similar vision benefits as aflibercept over a period of 56 weeks. Additionally, the study will track the number of injections required and any changes in the retina’s structure and function over the full 96 weeks. This research aims to provide valuable information on the effectiveness of EYP-1901 as a treatment option for individuals with wet age-related macular degeneration.

The purpose of the study is to evaluate how safe and well-tolerated this method of delivering Ranibizumab is for patients with nAMD. Participants in the study will receive the treatment every 24 or 36 weeks, depending on the specific group they are assigned to. The study will monitor participants over a long period to gather information on any side effects or issues that may arise from the treatment. This will help researchers understand the potential benefits and risks associated with using the Port Delivery System for managing nAMD.

Throughout the study, participants will undergo regular check-ups to assess their vision and overall eye health. These assessments will help determine any changes in vision and identify any adverse effects related to the treatment. The study aims to provide valuable insights into the long-term use of the Port Delivery System with Ranibizumab for individuals with Neovascular Age-Related Macular Degeneration.

Participants in the study will receive injections of aflibercept in both eyes. The study will monitor the levels of the medication in the blood to see how it is absorbed and processed by the body. This will help researchers understand the effects of the medication when used in higher doses. The study will also include a comparison with a placebo to evaluate the effectiveness of the treatment.

The study will take place over a period of time, during which participants will receive regular injections and have their blood levels checked. This will help determine the maximum concentration of aflibercept in the blood. The information gathered from this study will contribute to understanding the safety and effectiveness of using high-dose aflibercept for treating these eye conditions.

The purpose of the study is to evaluate the effectiveness and safety of this combination treatment compared to using aflibercept alone. Participants in the study will receive injections directly into the eye, a method known as intravitreal use. The study will last for a period of 96 weeks, during which participants will receive regular injections and have their vision monitored to assess any changes.

Throughout the study, some participants will receive a placebo, which is a treatment that looks like the real medication but does not contain any active ingredients. This helps researchers understand the true effects of the medications being tested. The study will measure changes in vision and other eye health indicators to determine the success of the treatment. The goal is to find out if the combination of OPT-302 and aflibercept can provide better results for people with wet AMD.

The purpose of this study is to evaluate how effective and safe the combination of OPT-302 and ranibizumab is compared to using ranibizumab alone. Participants in the study will receive regular injections of these medications over a period of time. Some participants will receive both OPT-302 and ranibizumab, while others will receive only ranibizumab. There is also a possibility of receiving a placebo, which is an inactive substance. The study will monitor changes in vision and eye health to determine the effectiveness of the treatment.

Throughout the study, participants will have regular check-ups to assess their vision and the condition of their eyes. The study aims to see if the combination of these medications can improve vision more effectively than the standard treatment alone. This research could potentially lead to better treatment options for people with wet AMD, helping to preserve their vision and improve their quality of life.

The purpose of the study is to evaluate how well an 8 mg dose of aflibercept works over a period of 32 weeks in patients who have previously been treated with another medication called faricimab and a lower dose of aflibercept (2 mg). The study will observe if the treatment can be extended over time without the return of fluid in the eye, which is a sign of the disease’s activity. Participants will receive regular injections and attend clinic visits to monitor their eye health and the effectiveness of the treatment.

Throughout the study, the main focus will be on the ability of aflibercept to maintain eye health by extending the time between treatments while keeping the eye free of fluid. The study will also track the number of injections needed and any changes in vision. This research aims to provide valuable information on the potential benefits of using a higher dose of aflibercept for managing neovascular age-related macular degeneration.

The purpose of the study is to evaluate how effective Faricimab is compared to Aflibercept in terms of how long the treatment effects last. Participants in the study will receive either Faricimab or Aflibercept and will be monitored over a period of time to see how well their condition is managed. The study will look at how often the treatments need to be given and how well they work in reducing fluid in the eye, which is a common issue in nAMD.

Throughout the study, participants will have regular check-ups to monitor their eye health and the effectiveness of the treatment. The study aims to find out if Faricimab can extend the time between treatments compared to Aflibercept, potentially offering a more convenient treatment option for those with nAMD. The trial will last for a total of 56 weeks, with key assessments at 32 weeks and 56 weeks to determine the success of the treatment in managing the disease.

The purpose of the study is to see if RGX-314 is not worse than aflibercept in improving vision over a period of time. Participants in the study will receive either RGX-314 or aflibercept, and some may receive a placebo. The study will last for about 54 weeks, during which participants will have regular check-ups to monitor their vision and overall health. The study aims to find out if RGX-314 can help maintain or improve vision in people with nAMD, and if it can reduce the need for additional treatments.

Throughout the study, participants will undergo various assessments to track changes in their vision and any side effects they might experience. The study will also look at how often participants need additional treatments to manage their condition. By the end of the study, researchers hope to gather enough information to determine if RGX-314 is a safe and effective treatment option for people with neovascular age-related macular degeneration.

The purpose of the study is to see if RBS-001 is as effective and safe as Eylea in treating nAMD. Participants in the study will receive injections of either RBS-001 or Eylea directly into the eye, a method known as intravitreal use. The study will also use a substance called fluorescein sodium to help doctors see the blood vessels in the eye more clearly during certain tests. This is done through a process called fluorescence angiography, which involves injecting fluorescein sodium into a vein to highlight the blood vessels in the eye.

Throughout the study, participants will have their vision tested regularly to monitor changes. The main focus will be on the change in vision clarity, measured by a test called the ETDRS letter score, at different points in time, especially at 8 weeks after starting treatment. The study will last for up to 52 weeks, with regular check-ups to ensure the safety and effectiveness of the treatments. The goal is to determine if RBS-001 can provide similar benefits to Eylea for people with nAMD.

Participants are randomly assigned to receive either BP05 or Lucentis, and both the participants and the doctors will not know which treatment is given to maintain objectivity in the results. This type of study is known as “double-blind.” Some participants may also receive a placebo, a treatment with no active medication, to further assess the effectiveness of these drugs.

The study aims to assess how well these treatments can improve vision by measuring changes in visual acuity, which determines the clarity of vision, and other factors such as the size of areas affected by the disease in the eye. The study will involve several visits and tests over time to track improvements or side effects, helping to gather comprehensive data on the impacts of these treatments.

The purpose of this study is to ensure that the AVT06 pre-filled syringe is handled correctly and safely, and to evaluate the safety of the treatment when injected into the eye. Participants in the study will receive the treatment through an injection into the eye, known as intravitreal use. The study will follow participants over a period to monitor the safety and effectiveness of the treatment. There is also an optional extension phase for further observation.

Throughout the study, the focus will be on the successful administration of the treatment and monitoring any side effects related to the eye. The study aims to provide valuable information on the safe use of Aflibercept in treating these eye conditions, helping to improve treatment options for patients with these diseases.

The purpose of this study is to assess the safety and effectiveness of this combined treatment approach compared to the standard treatment, which typically involves only the use of anti-VEGF medications like aflibercept. Participants in the study will be randomly assigned to receive either the new treatment combination or the standard treatment. The study will be conducted over a period of time, with regular follow-up visits to monitor the participants’ eye health and vision. During these visits, various tests will be performed to evaluate the improvement in vision and the overall health of the eye.

This trial aims to provide valuable information on whether the new treatment approach can offer better outcomes for patients with SMH due to wet AMD. The study is designed to be thorough and carefully monitored to ensure the safety of all participants. The results of this trial could potentially lead to improved treatment options for individuals affected by this challenging eye condition.

The purpose of this study is to determine if there is a difference in the number of injections needed over two years for patients treated with either bevacizumab or aflibercept for wet AMD. Participants in the study will receive one of these treatments, or a placebo, and will be monitored over a period of two years. During this time, the study will track how many injections are required, as well as other factors like visual acuity, which is the clarity or sharpness of vision, and the thickness of the macula, which is the central part of the retina responsible for detailed vision.

Additional aspects being observed include intraocular pressure, which is the fluid pressure inside the eye, and the interval between treatment sessions. The study will also assess the cost-effectiveness of the treatments by measuring quality-adjusted life years, a way to evaluate the value of medical interventions. Participants’ vision-related quality of life will be evaluated using a questionnaire. The study aims to provide valuable insights into the effectiveness and efficiency of these treatments for wet AMD.